Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas

Endocrine Pathology

Volumn 17, Issue 4, 2006, Pages 387-398

  Luo, Zuojie ^a   Li, Jianling ^a   Qin, Yinfen ^a   Ma, Yan ^a   Liang, Xinghuan ^a   Xian, Jing ^a   Lu, Decheng ^a   Wei, Minyi ^a   Yang, Jack Y ^b   Yang, Mary Qu ^c   He, Zhiheng ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

hTERT; hTERT mRNA; Ki 67; p27kip1; Pheochromocytoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ADOLESCENT; ADRENAL MEDULLA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHEOCHROMOCYTOMA; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 34347350175     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-006-0010-4     Document Type: Article

References (31)

1. Nakamura TM, Cech TR. Reversing time: origin of telomerase. Cell 92:587-590, 1998.
2. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol 18:2626-2634, 2000.
3. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
4. Tang SJ, Dumot JA, Wang L, et al. Telomerase activity in pancreatic endocrine tumors. Am J Gastroenterol 97(4):1022-1030, 2002.
5. Umbricht CB, Conrad GT, Clark DP, et al. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin Cancer Res 10:5762-5768, 2004.
6. Orlando C, Gelmini S. Telomerase in endocrine and endocrine-dependent tumors. J Steroid Biochem Mol Biol 78(3):201-214, 2001.
7. Michalides RJ. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol 52:555-568, 1999.
8. KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 6:4073-4081, 2000.
9. kip-1 expression in colorectal adenocarcinomas is associated with tumor stage. Clin Cancer Res 10:1743-1752, 2004.
10. kip1 cyclin-dependent kinase inhibitors is regulated differently during human B cell differentiation. J Immunol 165:4346-4352, 2000.
11. Motti ML, Califano D, Troncone G, et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166:737-749, 2005.
12. kipl expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997.
13. Pace V, Pharmates E, Germann PG. Pheochromocytomas and ganglioneuromas in the aging rats: morphological and immunohistochemical characterization. Toxicol Pathol 30(4):492-500, 2002.
14. Isobe K, Yashiro T, Omura S, et al. Expression of the human telomerase reverse transcriptase in pheochromocytoma and neuroblastoma tissues. Endocr J 51(1):47-52, 2004.
15. Elder EE, Xu D, Hoog A, et al. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16(3):246-255, 2003.
16. Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551-566, 2002.
17. Linnoila RI, Keiser HR, Steinberg SM, et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180, 1990.
18. van der Harst E, Bruining HA, Jaap Bonjer H, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 191:175-180, 2000.
19. Kimura N, Watanabe T, Noshiro T, et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extraadrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16(1):23-32, 2005.
20. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959, 1997.
21. Hadar T, Shvero J, Yaniv E, et al. Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 11(1):45-49, 2005.
22. Bravaccini S, Sanchin MA, Amadori A, et al. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J Clin Pathol 58(9):911-914, 2005.
23. Culhaci N, Sagol O, Karademir S, et al. Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer 5:98, 2005.
24. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230, 1997.
25. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997.
26. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24(7):1167-1176, 2003.
27. Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1:249-255, 1995.
28. Boltze C, Mundschenk J, Unger N, et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metabol 88(9):4280-4286, 2003.
29. Kubota Y, Nakada T, Sasagawa I, et al. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 82:176-179, 1998.
30. Bamberger CM, Else T, Bamberger AM, et al. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes 107:272-275, 1999.
31. Isola JJ, Helin HJ, Helle MJ, et al. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 65:1180-1184, 1990.